Toosendanin Demonstrates Promising Antitumor Efficacy in Osteosarcoma by Targeting STAT3

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2017 Aug 8

PMID 28783167

Citations 58

Authors

T Zhang

J Li

F Yin

B Lin

Z Wang

J Xu

H Wang

D Zuo

G Wang

Y Hua

Z Cai

Affiliations

Soon will be listed here.

Abstract

Signal transducer and activator of transcription 3(STAT3) is an emerging target for cancer therapy. In this study, we identify Toosendanin (TSN) is an effective inhibitor of STAT3, leading to the impediment of various oncogenic processes in osteosarcoma. TSN selectively inactivates phospho-STAT3 (Tyr-705); subsequent molecular docking and in vitro SPR analysis uncover TSN directly binds to the SH2 domain of STAT3. Consequently, TSN blocks STAT3 dimerization and impairs the complex formation of STAT3 and epidermal growth factor receptor (EGFR). In an animal tumor model study, TSN is well tolerated, inhibits osteosarcoma growth and metastasis. In another osteosarcoma patient-derived xenografts (PDX) model, we find TSN triggers strong inhibitory effects on patient-derived tumors. Further studies show that TSN also displays activity against other solid tumors. Our preclinical work therefore supports that TSN acts as a novel inhibitor of STAT3 that blocks tumorigenesis in ostoesarcoma.

Citing Articles

Xenografting Human Musculoskeletal Sarcomas in Mice, Chick Embryo, and Zebrafish: How to Boost Translational Research.

Giusti V, Miserocchi G, Sbanchi G, Pannella M, Hattinger C, Cesari M Biomedicines. 2024; 12(8).

PMID: 39200384 PMC: 11352184. DOI: 10.3390/biomedicines12081921.

The role of programmed cell death in osteosarcoma: From pathogenesis to therapy.

Liu S, Liu C, Wang Y, Chen J, He Y, Hu K Cancer Med. 2024; 13(10):e7303.

PMID: 38800967 PMC: 11129166. DOI: 10.1002/cam4.7303.

Overexpression of miR-506-3p reversed doxorubicin resistance in drug-resistant osteosarcoma cells.

Wang X, Ding R, Fu Z, Yang M, Li D, Zhou Y Front Pharmacol. 2024; 15:1303732.

PMID: 38420199 PMC: 10899521. DOI: 10.3389/fphar.2024.1303732.

Antitumor effect of toosendanin on oral squamous cell carcinoma via suppression of p-STAT3.

Wu Y, Chen L, Feng C, Wang T, He S, Zheng D BMC Oral Health. 2023; 23(1):846.

PMID: 37946196 PMC: 10634166. DOI: 10.1186/s12903-023-03602-x.

Toosendanin Restrains Idiopathic Pulmonary Fibrosis by Inhibiting ZEB1/CTBP1 Interaction.

Li X, Bai Z, Li Z, Wang J, Yan X Curr Mol Med. 2023; 24(1):123-133.

PMID: 37138491 PMC: 10804237. DOI: 10.2174/1566524023666230501205149.

References

Nicolson G . Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev. 1988; 7(2):143-88. DOI: 10.1007/BF00046483. View

Fossey S, Liao A, McCleese J, Bear M, Lin J, Li P . Characterization of STAT3 activation and expression in canine and human osteosarcoma. BMC Cancer. 2009; 9:81. PMC: 2666757. DOI: 10.1186/1471-2407-9-81. View

Stahl N, Farruggella T, Boulton T, Zhong Z, Darnell Jr J, Yancopoulos G . Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science. 1995; 267(5202):1349-53. DOI: 10.1126/science.7871433. View

Haan S, Hemmann U, Hassiepen U, Schaper F, Schneider-Mergener J, Wollmer A . Characterization and binding specificity of the monomeric STAT3-SH2 domain. J Biol Chem. 1999; 274(3):1342-8. DOI: 10.1074/jbc.274.3.1342. View

Darnell Jr J, Kerr I, Stark G . Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994; 264(5164):1415-21. DOI: 10.1126/science.8197455. View

Niu G, Wright K, Huang M, Song L, Haura E, Turkson J . Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002; 21(13):2000-8. DOI: 10.1038/sj.onc.1205260. View

Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P . A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007; 13(13):3989-98. DOI: 10.1158/1078-0432.CCR-07-0078. View

Yu H, Pardoll D, Jove R . STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009; 9(11):798-809. PMC: 4856025. DOI: 10.1038/nrc2734. View

Eckert M, Lwin T, Chang A, Kim J, Danis E, Ohno-Machado L . Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell. 2011; 19(3):372-86. PMC: 3072410. DOI: 10.1016/j.ccr.2011.01.036. View

10.

Valastyan S, Weinberg R . Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011; 147(2):275-92. PMC: 3261217. DOI: 10.1016/j.cell.2011.09.024. View

11.

Zhang T, Li S, Li J, Yin F, Hua Y, Wang Z . Natural product pectolinarigenin inhibits osteosarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibition. Cell Death Dis. 2016; 7(10):e2421. PMC: 5133974. DOI: 10.1038/cddis.2016.305. View

12.

Kang Y, Massague J . Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004; 118(3):277-9. DOI: 10.1016/j.cell.2004.07.011. View

13.

Isakoff M, Bielack S, Meltzer P, Gorlick R . Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. J Clin Oncol. 2015; 33(27):3029-35. PMC: 4979196. DOI: 10.1200/JCO.2014.59.4895. View

14.

Real P, Sierra A, de Juan A, Segovia J, Lopez-Vega J, Fernandez-Luna J . Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene. 2002; 21(50):7611-8. DOI: 10.1038/sj.onc.1206004. View

15.

Zhang X, Yue P, Fletcher S, Zhao W, Gunning P, Turkson J . A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol. 2010; 79(10):1398-409. PMC: 3188443. DOI: 10.1016/j.bcp.2010.01.001. View

16.

Ryu K, Choy E, Yang C, Susa M, Hornicek F, Mankin H . Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis. J Orthop Res. 2010; 28(7):971-8. DOI: 10.1002/jor.21088. View

17.

Nakajima M, Chop A . Tumor invasion and extracellular matrix degradative enzymes: regulation of activity by organ factors. Semin Cancer Biol. 1991; 2(2):115-27. View

18.

Zhang X, Sun Y, Pireddu R, Yang H, Urlam M, Lawrence H . A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. Cancer Res. 2013; 73(6):1922-33. PMC: 4030628. DOI: 10.1158/0008-5472.CAN-12-3175. View

19.

Sakai I, Takeuchi K, Yamauchi H, Narumi H, Fujita S . Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood. 2002; 100(8):2926-31. DOI: 10.1182/blood-2002-01-0073. View

20.

Devarajan E, Huang S . STAT3 as a central regulator of tumor metastases. Curr Mol Med. 2009; 9(5):626-33. DOI: 10.2174/156652409788488720. View